跳至主要内容
临床试验/JPRN-UMIN000024316
JPRN-UMIN000024316已完成未知

Studies of efficacy and safety of the combined use of febuxostat and inosine for patients with glucose intolerance, and changes of blood and urine purine compounds. - Effect of febuxostat and inosine on glucose intolerance

Tsukuba International Clinical Pharmacology Clinic0 个研究点目标入组 5 人开始时间: 2017年8月31日最近更新:

试验速览

阶段
未知
状态
已完成
发起方
入组人数
5

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 60years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1.Routine user of medicine or supplement. 2.Subject who is currently being treated for diabetes. 3.Subject who has or had renal function disorder. 4.Subject with a history of gout, hyperuricemia or urolithiasis. 5.Subject who has a history of renal disorder. 6.Subject who has or had hypersensitivity, idiosyncracy (allergy) to drug. 7.Subjects taking azathioprine, mercaptopurine or other purine analogs 8.Subject with a disease or a disorder in heart, kidney, pulmonary organ, digestive organ or blood function that are considered to affect absorption, distribution, metabolism or excretion of a drug. 9.Subject who participated in another clinical study for a drug with a new compound within 4 weeks before the administration of drug in the present study. 10.Subject who donated 400 mL of blood within 12 weeks, 200 mL of blood within 4 weeks or blood components within 2 weeks. 11.Subject who used other drugs (including herbs) or supplements within 2 weeks before the administration of drug in this study. 12.Sujbect who plans to take other drugs (including herbs) or supplements before the end of the present study. 13.Subject who was judged not to be appropriate by the principal investigator or sub investigators by other reasons.

研究者

发起方
Tsukuba International Clinical Pharmacology Clinic

相似试验